Interpace Biosciences (IDXG) investor relations material

Executive summary

• Q4 2025 revenue was $9.2 million and full year 2025 revenue was $38.7 million, reflecting a transition to a thyroid-only diagnostics business.

• Income from continuing operations was $22.8 million for Q4 and $25.0 million for FY 2025, driven by a one-time, non-cash tax-related accounting adjustment.

• Thyroid test volume increased 11% year-over-year in Q4 and 13% for the full year; thyroid revenue rose 14% in Q4 and 21% for the year.

• The company fully paid off its debt in Q4 2025 and increased cash availability by $4.3 million year-over-year.

• Transitioned away from PancraGEN, focusing exclusively on thyroid diagnostics.

Financial highlights

• Q4 2025 revenue decreased 26% from the prior year quarter but increased 20% from pro forma results; FY 2025 revenue decreased 18% from the prior year but increased 17% from pro forma.

• Gross profit margin was 66% in Q4 2025 (up from 64% prior year) and 62% for FY 2025 (down from 64% prior year).

• Q4 operating income was $1.6 million, down from $2.1 million prior year; FY operating income was $4.1 million, down from $8.1 million.

• Adjusted EBITDA for Q4 was $1.7 million (down from $2.2 million prior year); FY Adjusted EBITDA was $5.4 million (down from $8.7 million).

• Q4 cash collections were $9.6 million; FY cash collections were $41.7 million.

Outlook and guidance

• Targeting approximately 16% year-over-year thyroid revenue growth in 2026.

• Focused on scaling thyroid test volume, deeper adoption within existing accounts, and productivity gains through automation.